专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5653980A Vaccine comprising part of constant region of IgE for treatment of IgE-mediated allergic reactions 失效
标题翻译：疫苗包含用于治疗IgE介导的过敏反应的IgE恒定区的一部分
公开(公告)号：US5653980A
公开(公告)日：1997-08-05
申请号：US196227
申请日：1994-03-23
申请人： Lars T. Hellman
发明人： Lars T. Hellman
IPC分类号： A61K39/00 , A61K39/385 , A61K39/39 , A61K39/395 , A61P37/08 , C07K16/42 , C07K17/02 , C12N1/21 , C12N15/09 , C12R1/19 , A61K39/44 , C12P21/08
CPC分类号： C07K16/4291 , C07K17/02 , A61K39/00 , Y10S424/80 , Y10S424/801 , Y10S424/805 , Y10S424/809 , Y10S424/81 , Y10S530/862 , Y10S530/867 , Y10S530/868
摘要： The invention relates to a vaccine, preferably for human use, against IgE-mediated allergic reactions. The vaccine contains a protein having the entire amino acid sequence of the constant CH2-CH3 domains of the epsilon chain of the IgE molecule or a structurally stable unit of said amino acid sequence, the protein optionally being coupled to one or more heterologous carrier proteins, and optionally containing an adjuvant. The vaccine is injected, with or without adjuvant, to raise the concentration of endogenous anti-IgE antibodies in the plasma of allergy subjects. In practice, the vaccine can be used against all types of IgE-mediated allergies since the antibodies are not dependent of the antigen specificity of the IgE molecule but will reduce the total IgE pool of the subject. Therefore, the vaccine is aimed at being used for treatment of subjects having different types of IgE-mediated allergies. The increased concentrations of anti-IgE antibodies reduces the free pool of antigen-specific IgE, which thereby strongly reduces the risk for an allergen-mediated release of the physiologically highly active substances which are stored or produced in connection with granula release from mast cells and basophilic leucocytes.
摘要翻译： PCT No.PCT / SE92 / 00673 Sec。 371日期1994年3月23日 102（e）日期1994年3月23日PCT提交1992年9月25日PCT公布。出版物WO93 / 05810 日期1994年4月1日本发明涉及针对IgE介导的过敏反应的优选用于人类的疫苗。疫苗含有蛋白质，其具有IgE分子的ε链的恒定CH2-CH3结构域的全部氨基酸序列或所述氨基酸序列的结构稳定的单位，所述蛋白质任选与一种或多种异源载体蛋白偶联，并任选地含有佐剂。用或不含佐剂注射疫苗以提高过敏体血浆中内源性抗IgE抗体的浓度。实际上，疫苗可以用于所有类型的IgE介导的过敏，因为抗体不依赖于IgE分子的抗原特异性，而是减少受试者的总IgE池。因此，疫苗旨在用于治疗具有不同类型的IgE介导的过敏症的受试者。抗IgE抗体的增加浓度降低了抗原特异性IgE的游离池，从而强烈地降低了与肥大细胞释放颗粒释放有关的储存或产生的生理高活性物质的过敏原介导释放的风险，嗜碱性白细胞。

IPRDB

热门服务

关于我们

友情链接

联系方式